Study: NCT03610334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (2.5-60.0mg) oral capsule
Description: SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (2.5-60.0mg) oral capsule
Description: SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (2.5-60.0mg) oral capsule
Description: SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (2.5-60.0mg) oral capsule
Description: SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (2.5-60.0mg) oral capsule
Description: SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (2.5-60.0mg) oral capsule
Description: SAD phase: IFB-088 will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (2.5-60.mg) oral capsule
Description: SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (2.5-60.mg) oral capsule
Description: SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (2.5-60.mg) oral capsule
Description: SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (2.5-60.mg) oral capsule
Description: SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (2.5-60.mg) oral capsule
Description: SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (2.5-60.mg) oral capsule
Description: SAD phase: placebo (microcrystalline cellulosis) will be administered during 1 day, in one (2.5mg) or 2 (5.0-60.0mg) intakes separated by an interval of 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (15.0-50.0mg) oral capsule
Description: MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (15.0-50.0mg) oral capsule
Description: MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IFB-088 (15.0-50.0mg) oral capsule
Description: MAD phase: multiple doses of IFB-088 (15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral (15.0-50.0mg) capsule
Description: MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral (15.0-50.0mg) capsule
Description: MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral (15.0-50.0mg) capsule
Description: MAD phase: multiple doses of placebo (microcrystalline cellulosis, 15.0-50.0mg) will be administered daily during 14 days, in two intakes, separated by an interval of 12 hours.